Appendix 4D
Filed with ASX · · 3 pages · English
On 6ix: 6ix.com/news/appendix-4d-56
There were no dividends paid or declared during the current financial period. Comments The loss for the consolidated entity after providing for income tax amounted to $3,395,877 (31 December 2024: $2,374,662). Financial performance During the 6-month period to 31 December 2025 (H1FY26), the consolidated entity generated ordinary revenue of $339,227 from sales, system rentals and the provision of s
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Initiates Head & Neck Cancer Imaging Study
- Optiscan Partners with ACL to Advance Digital Pathology
- Appendix 4E - Preliminary Final Report
- Entitlement Issue Prospectus
Later from Optiscan Imaging
- Optiscan Submits InSpecta FDA Dossier
- Optiscan Receives $1.69m R&D Tax Refund
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Optiscan Launches InSpecta Device for Veterinary Medicine
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging